Persistence and Failure Rates of Monotherapy Etanercept in Biologic-Naïve Psoriasis Patients: A Retrospective Study

August 2016 | Volume 15 | Issue 8 | Editorials | 1029 | Copyright © August 2016

Shivani P. Reddy BS,a Vidhi V. Shah BS,b Elaine J. Lin BS,c Alexander Egeberg MD PhD,d and Jashin J. Wu MDe

aUniversity of Illinois at Chicago College of Medicine, Chicago, IL
bUniversity of Missouri-Kansas City School of Medicine, Kansas City, MO
cLoma Linda University School of Medicine, Los Angeles, CA
dHerlev and Gentofte Hospital, Hellerup, Denmark
eKaiser Permanente Los Angeles Medical Center, Los Angeles, CA

Clinical trial data on the efficacy of etanercept for the treatment of moderate-to-severe plaque psoriasis may differ from real-world results, yet etanercept remains a widely used therapy despite this and the advent of newer biologic agents. We performed a retrospective study of psoriasis patients using monotherapy etanercept in order to determine how our efficacy data compares to that of pivotal trials.1,2 Specifically, we determined the persistence and failure rates, mean and median duration in patients who failed therapy, and drug survival amongst the entire cohort.
This study was conducted at the Kaiser Permanente Los Angeles Medical Center on 41 biologic-naïve severe psoriasis patients seen between 2004 and 2015. Inclusion criteria was minimum 3 month etanercept use on standard dosing (50 mg twice weekly for 12 weeks, followed by 50 mg weekly thereafter), and at least 10% body surface area coverage. Failure of treatment was defined as the need for concomitant therapy, either an oral medication (methotrexate, cyclosporine, acitretin) or phototherapy, or to switch to a different agent (oral agent or a biologic ie adalimumab, infliximab, ustekinumab, or secukinumab). Concomitant therapy for conditions other than psoriasis did not constitute failure criteria, and patients who discontinued therapy due to insurance coverage changes were excluded from this study. Failure date was set as the initiation date of the new systemic agent or first phototherapy session. Drug survival, or treatment retention, of etanercept therapy was calculated using the Kaplan-Meier method. This study was approved by the Kaiser Permanente Southern California Institutional Review Board.
Our results showed that 24.4% of patients (10/41) persisted on etanercept monotherapy from a range of 3.9 months to 10.5 years before the end of study, and for an average of 4.6 years (1662 days) and a median of 3.8 years (1401 days). The remaining 75.6% (31/41) of patients had used etanercept for an average of 2.7 years (993 days), and a median of 2.3 years (850 days) before failure. Figure 1 illustrates the distribution of treatment length in these two groups.
Nineteen percent (8/41) of patients had co-existing psoriatic arthritis, and 6 of these patients eventually failed therapy after an average of 2.4 years (874 days). The mean drug survival time in the entire cohort was 3.8 years (1396 days), with a 95% confidence interval (CI) of 2.8-4.8 years (1026-1764 days). The median drug survival was 3.3 years (1217 days). Figure 2 plots the cumulative survival probability using Kaplan-Meier analysis.
A study from the Netherlands3 found the mean survival duration for etanercept to be 3.8 years with a maximum treatment duration of 7.5 years, similar to our findings. However, a major difference from this study is that ours included solely biologic-naïve patients. Gniadecki et al4 found a 2.5-year median drug survival rate amongst 449 patients treated with etanercept, and a 2.75-year
table 1